Similar articles

• Interferons in renal-cell carcinoma: status and prospects.

  De Mulder PH, Debruyne FM, Beniers AJ. De Mulder PH, et al. Prog Clin Biol Res. 1990;348:49-59. Prog Clin Biol Res. 1990. PMID: 1696737 Review. No abstract available.
• Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trials.

  Otto U, Schneider AW, Conrad S, Klosterhalfen H. Otto U, et al. Prog Clin Biol Res. 1990;350:275-82. Prog Clin Biol Res. 1990. PMID: 2117287 Clinical Trial. No abstract available.
• Recombinant alpha-interferon plus vinblastine in metastatic renal-cell cancer: analysis of response and survival in 58 evaluable patients.

  Bergerat JP, Ford J, Herbrecht R, Dufour P, Oberling F, Jacqmin D, Bollack C, Prevot G, Salze P, Jurascheck F, et al. Bergerat JP, et al. Prog Clin Biol Res. 1990;348:137-50. Prog Clin Biol Res. 1990. PMID: 2385604 No abstract available.
• Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.

  Figlin RA, Pierce WC, Belldegrun A. Figlin RA, et al. Semin Oncol. 1993 Dec;20(6 Suppl 9):11-5. Semin Oncol. 1993. PMID: 8284686 Review. No abstract available.
• Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.

  Marumo K, Tazaki H. Marumo K, et al. Prog Clin Biol Res. 1990;350:263-73. Prog Clin Biol Res. 1990. PMID: 2117286 No abstract available.